%0 Journal Article
%T A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma.
%A Goodman CD
%A DeMonte F
%A Nguyen TP
%A Garden AS
%A Wang CH
%A Wang XA
%A Diao K
%A Lee A
%A Reddy J
%A Moreno A
%A Spiotto M
%A Fuller CD
%A Rosenthal D
%A Ferrarotto R
%A Raza SM
%A Su SY
%A Warner A
%A Hanna E
%A Phan J
%J Head Neck
%V 0
%N 0
%D 2024 Jul 29
%M 39073252
%F 3.821
%R 10.1002/hed.27887
%X <B>BACKGROUND: </B>Treatment for dural recurrence of olfactory neuroblastoma (ONB) is not standardized. We assess the outcomes of stereotactic body radiotherapy (SBRT) in this population.<BR><B>METHODS: </B>ONB patients with dural recurrences treated between 2013 and 2022 on a prospective registry were included. Tumor control, survival, and patient-reported quality of life were analyzed.<BR><B>RESULTS: </B>Fourteen patients with 32 dural lesions were evaluated. Time to dural recurrence was 58.3 months. Thirty lesions (94%) were treated with SBRT to a median dose of 27 Gy in three fractions. Two patients (3 of 32 lesions; 9%) developed in-field radiographic progression, five patients (38%) experienced progression in non-contiguous dura. Two-year local control was 85% (95% CI: 51-96%). There were no >grade 3 acute toxicities and 1 case of late grade 3 brain radionecrosis.<BR><B>CONCLUSIONS: </B>In this largest study of SBRT reirradiation for ONB dural recurrence to date, high local control rates with minimal toxicity were attainable.